Eleven days after the Albanese government established Australia's AI Biosecurity Office, Australians for AI Safety published a public letter to Agriculture Minister Julie Collins on May 4 that named the providers and the chokepoint. [1] The letter — signed by dozens of biosecurity and AI-industry researchers — calls on the Department of Agriculture to require synthetic-nucleic-acid screening at the Biosecurity Import Conditions database (BICON) gateway, and names three of the largest commercial synthesis providers — Twist Bioscience, Integrated DNA Technologies, and GenScript — as members of the International Gene Synthesis Consortium that already screen orders for sequences of concern voluntarily. [1] The same week, in Washington, the National Security Board sat in its thirteenth day of disbandment with no replacement office and no HHS counterparty named. The two clocks run in parallel. The one running fast is Australia's.

Yesterday's paper named the comparison. The structural fact has not changed; the May 4 BICON-screening letter is now a specific statutory recommendation, not a general worry. The new Australian office, established April 26 with a $29.9 million establishment commitment under the National AI Plan, integrates security, science, and policy expertise to assess catastrophic AI-bio risks. [2] Minister Collins received the letter on May 4. The responding regulatory question is concrete: should every synthetic-nucleic-acid order routed through Australia's import-permit system require sequence-of-concern screening at the provider end, with the provider's screening report logged against the BICON permit? The answer would mark the first time a Westminster government has codified a statutory chokepoint specifically targeting AI-enabled bioweapon assembly.

The U.S. position on the same week is the absence of a position. The disbanded National Security Board sits without a replacement; the AI Safety Institute analog has not been re-established at HHS, OSTP, or the Department of Commerce; the Anthropic civilian-agency executive order remains at the table-read stage in the White House without a published date for issuance. The New York Times pathogen-assembly transcripts that produced congressional staff letters in mid-April have not received a federal response. The Bondi memo's compulsory-process posture toward press-freedom enforcement has consumed the Justice Department's bandwidth. The federal architecture that would issue a U.S. equivalent to the BICON-screening recommendation does not currently exist. That is not a rhetorical claim; it is the procurement record. There is no agency-level requisition for synthetic-nucleic-acid screening, no analogous chokepoint statute under review at OMB, and no academy letter that has produced an executive-branch response.

The International Gene Synthesis Consortium is the bridge. Its members already screen orders against sequence-of-concern lists. They publish their screening protocols in technical documents available on the IGSC website. They are commercial suppliers operating in a market where most of their customers are universities and pharmaceutical companies. The Australians-for-AI-Safety letter does not ask Twist, IDT, or GenScript to do something they are not already doing voluntarily. It asks the Australian government to require it as a condition of import permits. The technical lift is small. The political lift is in the precedent — that a national biosecurity agency is now using statutory authority to enforce what had been a voluntary industry norm. The Australian Department of Agriculture has weeks of consultation work ahead of it before BICON regulations could be amended. But the trajectory is set.

The science is the reason the chokepoint matters. A synthetic-nucleic-acid order placed by a researcher in Australia is fulfilled by a synthesis lab that may be in California, Iowa, or Beijing. The order is shipped through the international supply chain. The receiving lab in Canberra or Melbourne assembles the synthesized fragments into a working biological agent — a process that can take days to weeks depending on the assembly approach. The bottleneck for malicious assembly is the synthesis provider, which has the capacity to refuse orders it identifies as potentially dangerous. The point of the BICON-screening recommendation is to require the synthesis provider to screen the order before fulfillment, and to log the screening result against an Australian import permit before the synthesized DNA crosses the border. The screening can be technical (sequence-matching against pathogen databases) or operational (institutional verification of the requesting lab). Either way, the import permit is the chokepoint where the Australian government can enforce.

Inside the Australian government, the new AI Biosecurity Office and the Inspector-General of Biosecurity, Dr. Melissa McEwen — who began her five-year term in October 2025 — are the operational counterparties. [3] The taskforce convened by Minister Collins is the high-level political response. The May 4 letter names Twist, IDT, and GenScript not as targets but as cooperating partners. That distinction is a governance signal: Australia's AI biosecurity strategy starts from the assumption that the synthesis providers are infrastructure, not adversaries. The U.S. analog assumption — that AI biosecurity will require similar industry partnership — is the one that has been suspended by the NSB disbandment. There is no current U.S. forum at which the IGSC can bring its members' screening protocols into a public regulatory conversation.

The plain-English version of the gap, for a reader who has not been tracking either thread: a Westminster government has just told its biosecurity regulator to think carefully about how AI is changing the bioweapon-assembly risk, and has named the specific border-permit system that should serve as the chokepoint. The U.S. equivalent office was disbanded thirteen days ago and has not been replaced. That is the operative fact. The two clocks running on the same week — Day 11 in Canberra, Day 8 of federal silence in Washington — produce the cleanest comparative governance receipt the AI-bio thread has yielded this year. By the time Minister Collins responds — likely within the week, as parliamentary protocol on signed academy letters typically requires — the U.S. silence will be at Day 14 with no announced timeline. The comparative read is not flattering for Washington.

-- KENJI NAKAMURA, Tokyo